BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35779291)

  • 1. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P3
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Blankenship L; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Blankenship L; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
    Geng ZZ; Atla S; Shaabani N; Vulupala V; Yang KS; Alugubelli YR; Khatua K; Chen PH; Xiao J; Blankenship LR; Ma XR; Vatansever EC; Cho CD; Ma Y; Allen R; Ji H; Xu S; Liu WR
    J Med Chem; 2023 Aug; 66(16):11040-11055. PubMed ID: 37561993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
    Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
    ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
    Hicks EG; Kandel SE; Lampe JN
    Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
    Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
    Geng ZZ; Atla S; Shaabani N; Vulupala VR; Yang KS; Alugubelli YR; Khatua K; Chen PC; Xiao J; Blankenship LR; Ma XR; Vatansever EC; Cho CC; Ma Y; Allen R; Ji H; Xu S; Liu WR
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
    Macip G; Garcia-Segura P; Mestres-Truyol J; Saldivar-Espinoza B; Pujadas G; Garcia-Vallvé S
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor.
    Hu X; Lin C; Xu Q; Zhou X; Zeng P; McCormick PJ; Jiang H; Li J; Zhang J
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.